Form 13-F position report

SORRENTO THERAPEUTICS INC

Reported by AlphaMark Advisors LLC

SRNEQ CUSIP 83587F202 Manager CIK 0001348183

Reported 4,000 shares, unchanged from the prior quarter.

Reported value -11.1%; share count 0.0% vs. the prior quarter.

Unchanged
% of reported 13F value < 0.01% This manager · Q2 2022
Shares 4,000 Quarter-end amount reported
Reported value $8,000 Fair value at quarter end
Consecutive quarters held 3 Through Q2 2022

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2021-12-31 7000
2022-03-31 9000
2022-06-30 8000
2022-09-30 6000
2022-12-31 3000
2023-03-31 0
2023-09-30 0
2023-12-31 0
2024-03-31 0
2024-06-30 0
2024-09-30 0

Quarterly position history

How this manager's reported quarter-end position changed over time.

11 quarters
Quarterly reported position history for SORRENTO THERAPEUTICS INC held by AlphaMark Advisors LLC.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q3 2024 Reduced 0 -2,135 (-100.0%) 0 $0 2024-10-16
Q2 2024 Unchanged 2,135 0 (0.0%) 0 $0 2024-07-17
Q1 2024 Unchanged 2,135 0 (0.0%) 0 $0 2024-04-18
Q4 2023 Reduced 2,135 -1,000 (-31.9%) 0 $0 2024-01-19
Q3 2023 New 3,135 +3,135 (0.0%) 0 $0 2023-10-31
Q1 2023 Reduced 0 -3,135 (-100.0%) 0 $0 2023-05-04
Q4 2022 Reduced 3,135 -865 (-21.6%) < 0.01% $3,000 2023-02-06
Q3 2022 Unchanged 4,000 0 (0.0%) < 0.01% $6,000 2022-11-14
Q2 2022 Unchanged 4,000 0 (0.0%) < 0.01% $8,000 2022-08-11
Q1 2022 Added 4,000 +2,500 (166.7%) < 0.01% $9,000 2022-05-02
Q4 2021 New 1,500 +1,500 (0.0%) < 0.01% $7,000 2022-02-09

Who else reported the position

242 managers reported SORRENTO THERAPEUTICS INC for Q2 2022.

Managers reporting SORRENTO THERAPEUTICS INC in Q2 2022.
Manager Activity Shares Change % of reported 13F Reported value Tenure
STATE STREET CORPORATION Added 39,661,099 +5,700,215 < 0.01% $79,719,000 33 qtrs
BlackRock Inc Added 33,950,557 +11,915,668 < 0.01% $68,242,000 29 qtrs
VANGUARD GROUP INC Added 20,896,424 +4,995,039 < 0.01% $42,002,000 35 qtrs
GEODE CAPITAL MANAGEMENT LLC Added 6,892,947 +1,906,514 < 0.01% $13,854,000 34 qtrs
D E Shaw & Co Inc Reduced 5,881,402 -1,360,489 0.01% $11,822,000 19 qtrs
NORTHERN TRUST CORPORATION Added 3,450,139 +633,201 < 0.01% $6,934,000 34 qtrs
JPMorgan Chase & Co Reduced 3,268,517 -29,062 < 0.01% $6,570,000 21 qtrs
MORGAN STANLEY Reduced 2,972,031 -309,183 < 0.01% $5,972,000 34 qtrs
NORGES BANK Added 2,901,483 +717,900 < 0.01% $5,831,981 4 qtrs
CHARLES SCHWAB INVESTMENT MANAGEMENT INC Added 2,766,904 +565,217 < 0.01% $5,562,000 18 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
June 30, 2022
Filed
August 11, 2022
Filing type
13F-HR
Position type
COM

Voting authority reported

Sole
0
Shared
0
None
4,000

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.